Literature DB >> 11721752

Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables.

P S Rabinovitch1, G Longton, P L Blount, D S Levine, B J Reid.   

Abstract

OBJECTIVES: Barrett's esophagus develops in 5-10% of patients with gastroesophageal reflux disease and predisposes to esophageal adenocarcinoma. We have previously shown that a systematic baseline endoscopic biopsy protocol using flow cytometry with histology identifies subsets of patients with Barrett's esophagus at low and high risk for progression to cancer. In this report, we further examined cytometric variables to better define the characteristics that best enable DNA cytometry to help predict cancer outcome.
METHODS: Patients were prospectively evaluated using a systematic endoscopic biopsy protocol, with baseline histological and flow cytometric measurements as predictors and with cancer as the outcome.
RESULTS: A receiver operating curve analysis demonstrated that a 4N fraction cut point of 6% was optimal to discriminate cancer risk (relative risk [RR] = 11.7, 95% CI = 6.2-22). The 4N fractions of 6-15% were just as predictive of cancer as were fractions of >15%. We found that only aneuploid DNA contents of >2.7N were predictive of cancer (RR = 9.5, CI = 4.9-18), whereas those patients whose sole abnormality was an aneuploid population with DNA content of < or =2.7 had a low risk for progression. The presence of both 4N fraction of >6% and aneuploid DNA content of >2.7N was highly predictive of cancer (RR = 23, CI = 10-50). S phase was a predictor of cancer risk (RR = 2.3, CI = 1.2-4.4) but was not significant when high-grade dysplasia was accounted for.
CONCLUSIONS: Flow cytometry is a useful adjunct to histology in assessing cancer risk in patients with Barrett's esophagus. Careful examination of cytometric variables revealed a better definition of those parameters that are most closely associated with increased cancer risk.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11721752      PMCID: PMC1559994          DOI: 10.1111/j.1572-0241.2001.05261.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  64 in total

1.  The economic impact of the diagnosis of dysplasia in Barrett's esophagus.

Authors:  J J Ofman; K Lewin; C Ramers; A Ippoliti; D Lieberman; W Weinstein
Journal:  Am J Gastroenterol       Date:  2000-10       Impact factor: 10.864

Review 2.  Chromosomal abnormalities in leukemia and lymphoma: clinical and biological significance.

Authors:  M M Le Beau; J D Rowley
Journal:  Adv Hum Genet       Date:  1986

Review 3.  Barrett's esophagus.

Authors:  S J Spechler; R K Goyal
Journal:  N Engl J Med       Date:  1986-08-07       Impact factor: 91.245

4.  Cell proliferation in esophageal columnar epithelium (Barrett's esophagus).

Authors:  J J Herbst; M M Berenson; D W McCloskey; W C Wiser
Journal:  Gastroenterology       Date:  1978-10       Impact factor: 22.682

5.  The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus.

Authors:  A J Cameron; B J Ott; W S Payne
Journal:  N Engl J Med       Date:  1985-10-03       Impact factor: 91.245

6.  Cell proliferation in three types of Barrett's epithelium.

Authors:  L J Pellish; J A Hermos; G L Eastwood
Journal:  Gut       Date:  1980-01       Impact factor: 23.059

7.  Accessibility of DNA in situ to various fluorochromes: relationship to chromatin changes during erythroid differentiation of Friend leukemia cells.

Authors:  Z Darzynkiewicz; F Traganos; J Kapuscinski; L Staiano-Coico; M R Melamed
Journal:  Cytometry       Date:  1984-07

8.  Flow-cytometric DNA analysis in primary breast carcinomas and clinicopathological correlations.

Authors:  S B Ewers; E Långström; B Baldetorp; D Killander
Journal:  Cytometry       Date:  1984-07

9.  Adenocarcinoma and Barrett's esophagus. An overrated risk?

Authors:  S J Spechler; A H Robbins; H B Rubins; M E Vincent; T Heeren; W G Doos; T Colton; E M Schimmel
Journal:  Gastroenterology       Date:  1984-10       Impact factor: 22.682

10.  DNA profile and tumour progression in patients with superficial bladder tumours.

Authors:  H Gustafson; B Tribukait; P L Esposti
Journal:  Urol Res       Date:  1982-02
View more
  99 in total

Review 1.  Biomarkers and molecular diagnosis of gastrointestinal and pancreatic neoplasms.

Authors:  Shelby D Melton; Robert M Genta; Rhonda F Souza
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10-05       Impact factor: 46.802

2.  Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus.

Authors:  Rebecca E Rudolph; Thomas L Vaughan; Alan R Kristal; Patricia L Blount; Douglas S Levine; Patricia C Galipeau; Laura J Prevo; Carissa A Sanchez; Peter S Rabinovitch; Brian J Reid
Journal:  J Natl Cancer Inst       Date:  2003-05-21       Impact factor: 13.506

Review 3.  Early events during neoplastic progression in Barrett's esophagus.

Authors:  Brian J Reid
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

4.  Narrow-band imaging: the significance of detail.

Authors:  Joseph M McKinley; Matthew J McKinley; Adel Y Daas; Sabo Tanimu; James S Barthel
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-10

5.  Reproducible two-dimensional capillary electrophoresis analysis of Barrett's esophagus tissues.

Authors:  James R Kraly; Megan R Jones; David G Gomez; Jane A Dickerson; Melissa M Harwood; Michael Eggertson; Thomas G Paulson; Carissa A Sanchez; Robert Odze; Ziding Feng; Brian J Reid; Norman J Dovichi
Journal:  Anal Chem       Date:  2006-09-01       Impact factor: 6.986

6.  Cell cycle phase abnormalities do not account for disordered proliferation in Barrett's carcinogenesis.

Authors:  Pierre Lao-Sirieix; Rebecca Brais; Laurence Lovat; Nicholas Coleman; Rebecca C Fitzgerald
Journal:  Neoplasia       Date:  2004 Nov-Dec       Impact factor: 5.715

Review 7.  Current Strategies in the management of Barrett's esophagus.

Authors:  Kenneth K Wang
Journal:  Curr Gastroenterol Rep       Date:  2005-06

Review 8.  Open questions in oesophageal adenocarcinogenesis.

Authors:  Carlo C Maley
Journal:  Gut       Date:  2007-07       Impact factor: 23.059

Review 9.  Screening and surveillance of Barrett's esophagus.

Authors:  Jeff Michalak; Ajay Bansal; Prateek Sharma
Journal:  Curr Gastroenterol Rep       Date:  2009-06

Review 10.  History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus.

Authors:  Stuart Jon Spechler; Rebecca C Fitzgerald; Ganapathy A Prasad; Kenneth K Wang
Journal:  Gastroenterology       Date:  2010-01-18       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.